Introduction
============

Human angiotensin I-converting enzyme (ACE; EC3.4.15.1) is a zinc metallopeptidase that plays a critical role in blood pressure regulation \[[@b1]--[@b7]\] by catalysing the proteolysis of angiotensin I to the vasopressor angiotensin II \[[@b8]--[@b10]\]. There are two isoforms of human ACE: in somatic tissues, it exists as a glycoprotein composed of a mature single polypeptide chain of 1277 amino acids with two active centres, one in each of the N- and C-domains \[[@b11]\]. Testis ACE (tACE) is identical to the C-terminal half of somatic ACE, except for a unique 36-residue sequence at its N-terminus \[[@b12]\]. Both domains are heavily glycosylated (the N-domain has 10 and the C-domain has 7 N-linked glycosylation sites), cleave angiotensin I, are dependent on chloride ion activation and share ∼ 55% amino acid sequence identity.

ACE inhibitors are widely used in clinical practice for the treatment of hypertension, heart failure, myocardial infarction and diabetic nephropathy. In addition, a number of studies have suggested that hypertension and oxidative stress are interdependent \[[@b13],[@b14]\]. Therefore, ACE inhibitors having antioxidant properties are considered beneficial for the treatment of hypertension. Because selenium compounds are known to exhibit better antioxidant behaviour than their sulfur analogues \[[@b15],[@b16]\], we have recently reported the synthesis, characterization and antioxidant activity of a number of selenium analogues of the clinically used ACE inhibitor captopril \[[@b17],[@b18]\]. It was shown that selenium analogues of captopril (SeCap) not only inhibit ACE activity, but also can effectively scavenge peroxynitrite, a strong oxidant found *in vivo* \[[@b19]\].

The two ACE homologues, AnCE and ACER, from a nonvertebrate, *Drosophila melanogaster*, have been studied in detail. AnCE is a single-domain protein, reported to have biochemical resemblance to C-domain ACE \[[@b20]\]. In addition the 3D structure(s) of native AnCE and AnCE in complex with ACE inhibitors has firmly established the high degree of conservation in the active site of ACE \[[@b21],[@b22]\].

Here, we report for the first time, structural details on the binding of one of the potent SeCaps ([Fig. 1](#fig01){ref-type="fig"}) to tACE and AnCE, as elucidated by X-ray crystallography at 2.4 and 2.35 Å resolution, respectively. Using these structures, we have been able to make a direct comparison of the previously determined structures of native tACE \[[@b23]\] and AnCE \[[@b22]\] with their respective complex with captopril \[[@b22],[@b24]\]. These structures are useful in understanding a selenolate ligand\'s coordination of zinc and its binding mode at the active site of ACE and its homologue AnCE.

![Chemical structures of captopril and SeCap.](febs0278-3644-f1){#fig01}

Results and Discussion
======================

tACE--SeCap complex
-------------------

The final structure contains a zinc ion, one SeCap inhibitor molecule, N-glycosylated carbohydrates at two potential binding sites (Asn72, Asn109) and 54 water molecules ([Table 1](#tbl1){ref-type="table"}). No noticeable conformational change in the protein is observed upon inhibitor binding. The topological arrangement of the final structure ([Fig. 2A](#fig02){ref-type="fig"}) is consistent with previously determined structures of tACE \[[@b23]\], as well as tACE in complex with captopril \[[@b24]\]. One bound SeCap molecule was unambiguously fitted in the catalytic site of tACE ([Fig. 3A](#fig03){ref-type="fig"}) with the aid of a clearly observed electron-density map.

###### 

X-ray diffraction data collection and refinement statistics. Values in parentheses are for last resolution shell. SeCap, selenium analogue of captopril; tACE, testis angiotensin I converting enzyme

                                                                                         tACE--SeCap inhibitor complex                              AnCE--SeCap inhibitor complex
  -------------------------------------------------------------------------------------- ---------------------------------------------------------- -----------------------------------------------------------
  Resolution (Å)                                                                         2.4                                                        2.35
  Space group                                                                            *P2*~*1*~*2*~*1*~*2*~*1*~ (one molecule/asymmetric unit)   *R3* (one molecule/asymmetric unit)
  Cell dimension (Å, deg)                                                                *a* = 56.1, *b* = 84.5, *c* = 132.3 α = β = γ = 90         *a* = 173.8, *b* = 173.8, *c* = 100.8 α = β = 90, γ = 120
  Total no. of observations                                                              117329                                                     179815
  No. of unique reflections                                                              23627                                                      44663
  Completeness (%)                                                                       97.4 (83.6)                                                94.7 (72.1)
  *I/σ(I)*                                                                               12.3 (2.2)                                                 11.5 (1.6)
  *R*~symm~[a](#tf1-1){ref-type="table-fn"}                                              0.09 (0.62)                                                0.075 (0.53)
  *R*~cryst~[b](#tf1-2){ref-type="table-fn"}*/R*~free~[c](#tf1-3){ref-type="table-fn"}   0.21/0.26                                                  0.20/0.24
  No. of protein atoms                                                                   4687                                                       4866
  No. of solvent atoms                                                                   54                                                         201
  No. of inhibitor atoms                                                                 14                                                         14
  Deviation from ideality                                                                                                                           
   Bond lengths (Å)                                                                      0.01                                                       0.01
   Bond angles (deg)                                                                     1.42                                                       0.88
  B-factor analysis                                                                                                                                 
   Protein all atoms                                                                     32.6                                                       35.3
   Protein main chain                                                                    32.2                                                       35.2
   Protein side chain                                                                    33.0                                                       35.3
   Solvent atoms                                                                         32.3                                                       35.4
   Inhibitor atoms                                                                       46.9                                                       51.0
   Zn^2+^/Cl^−^ ions (tACE); Zn^2+^ ion (AnCE)                                           35.7/44.0                                                  33.9
   Glycosylated sugars                                                                   52.7                                                       54.0

*R*~symm~ = Σ~*h*~Σ~*i*~\[\|*I*~*i*~(*h*) − \<I(*h*)\>\|/Σ~*h*~Σ~*i*~*I*~*i*~(*h*)\], where *I*~*i*~ is the *i*th measurement and *\<I*(*h*)*\>* is the weighted mean of all the measurements of *I(h)*.

*R*~cryst~ = Σ~*h*~*\|F*~*o*~ − *F*~*c*~*\|/*Σ~*h*~*F*~*o*~, where *F*~o~ and *F*~c~ are observed and calculated structure factor amplitudes of reflection *h*, respectively.

*R*~free~ is equal to *R*~cryst~ for a randomly selected 5% subset of reflections.

![(A) Structure of tACE (cyan) with inhibitor SeCap bound at the active site cavity (shown in spheres). The zinc ion (green sphere) bound in the active site and *N*-glycosylated sugars (brown sticks) at potential sites, Asn72, Asn109 are shown. Protein termini are labelled. (B) Structure of AnCE (blue) with inhibitor SeCap bound at the active site cavity (shown in spheres). The zinc ion (green sphere) bound in the active site and *N*-glycosylated sugars (brown sticks) at potential sites, Asn53, Asn196, Asn311 are shown.](febs0278-3644-f2){#fig02}

![(A) A stereo representation of tACE active site with bound inhibitor. The inhibitor molecule is shown in a stick model (brown) with the electron density map contoured at 1σ level. The zinc ion is shown as a green sphere and water molecules in light blue colour. Interacting residues are labeled and atoms are coloured as follows: red for oxygen, blue for nitrogen and purple for selenium. Hydrogen bonds are shown as dotted lines. (B) Comparison of SeCap (this study, left) and captopril (yellow sticks) binding \[[@b24]\] to tACE (right).](febs0278-3644-f3){#fig03}

The inhibitor SeCap molecule makes a direct interaction with the catalytic Zn^2+^ ion (distance 2.5 Å, [Table 2](#tbl2){ref-type="table"}) deep inside the active site channel ([Fig. 2A](#fig02){ref-type="fig"}), similar to the zinc coordination in tACE--captopril \[[@b24]\]. This interaction results in the formation of a zinc--selenolate complex. The inhibitor is anchored through the central carbonyl group and the proline carboxylate group. The proline residue of SeCap interacts with the S~2~′ subsite of the active site via two strong hydrogen bonds from two histidines (His513, 3.1 Å; His353, 2.6 Å). One oxygen atom of the proline carboxylate group is held by interactions with Tyr520 (2.7 Å), Gln281 (2.7 Å) and Lys511 (3.0 Å) ([Fig. 3A](#fig03){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}). In addition, it is held by seven hydrogen bonds including two mediated through water molecules, as calculated by [hbplus]{.smallcaps} \[[@b25]\] ([Table 2](#tbl2){ref-type="table"}). Thus, the interactions of SeCap with tACE residues are almost identical to those observed with captopril \[[@b24]\] ([Fig. 3B](#fig03){ref-type="fig"}), which is not too surprising considering the similarity between the two chemical structures ([Fig. 1](#fig01){ref-type="fig"}).

###### 

Hydrogen bond contacts of testis angiotensin I converting enzyme (tACE) with the selenium analogue of captopril (SeCap) inhibitor

                   Atom   Inhibitor atom   Distance (Å)
  ---------------- ------ ---------------- --------------
  tACE Residue                             
  His353           NE2    O1               2.6
  His513           NE2    O1               3.1
  Gln281           NE2    O2               2.7
  Lys511           NZ     O2               3.0
  Tyr520           OH     O2               2.7
  Zinc ion                                 
                   Zn     Se               2.5
  Water molecule                           
                   O      O3               3.0
                   O      Se               3.4

AnCE--SeCap complex
-------------------

The final structure contains a zinc ion, one inhibitor molecule, N-glycosylated carbohydrates at three potential binding sites (Asn53, Asn196, Asn311) and 201 water molecules ([Table 1](#tbl1){ref-type="table"}). No noticeable conformational change is observed upon inhibitor binding. The topological arrangement of the final structure ([Fig. 2B](#fig02){ref-type="fig"}) is consistent with previously determined structures of AnCE and AnCE in complex with captopril \[[@b21],[@b22]\]. One bound SeCap molecule was unambiguously fitted in the catalytic site of AnCE ([Fig. 4A](#fig04){ref-type="fig"}) with the aid of a clearly observed electron-density map.

![(A) A stereo representation of AnCE active site with bound inhibitor. The inhibitor molecule is shown in a stick model (brown) with the electron density map contoured at 1σ level. The zinc ion is shown as a green sphere and water molecules in light blue colour. Interacting residues are labeled and atoms are coloured as follows: red for oxygen, blue for nitrogen and purple for selenium. Hydrogen bonds are shown as dotted lines. (B) Comparison of SeCap (this study, left) and captopril (yellow sticks) binding \[[@b22]\] to AnCE (right).](febs0278-3644-f4){#fig04}

The inhibitor SeCap molecule makes a direct interaction with the catalytic Zn^2+^ ion, displacing the water that is bound in the native enzyme (distance 2.7 Å, [Table 3](#tbl3){ref-type="table"}) ([Fig. 4A](#fig04){ref-type="fig"}), similar to the zinc coordination in AnCE--captopril \[[@b21],[@b22]\]. This interaction results in the formation of a zinc--selenolate complex. The carboxy-end of the proline moiety and the central carbonyl interact with the extended S~1~′S~2~′-binding site locking the inhibitor in position. The proline residue of SeCap makes important contacts with the S2′ subsite via two strong hydrogen bonds from two histidines (His497, 3.1 Å; His337, 2.5 Å). One oxygen atom of the proline carboxylate group interacts with Tyr504 (2.5 Å), Gln265 (2.9 Å) and Lys495 (2.9 Å) through hydrogen and ionic bonds ([Fig. 4A](#fig04){ref-type="fig"}, [Table 3](#tbl3){ref-type="table"}). The central carbonyl of SeCap is held by His337 and His497. In addition, it is held by seven hydrogen bonds, including two hydrogen bonds mediated through water molecules, as calculated by [hbplus]{.smallcaps} \[[@b25]\] ([Table 3](#tbl3){ref-type="table"}). Thus, the interactions of SeCap with AnCE residues are almost identical to those observed with captopril \[[@b21],[@b22]\] ([Fig. 4B](#fig04){ref-type="fig"}).

###### 

Hydrogen bond contacts of AnCE with the selenium analogue of captopril (SeCap) inhibitor

                   Atom   Inhibitor atom   Distance (Å)
  ---------------- ------ ---------------- --------------
  AnCE residue                             
  Gln265           NE2    O2               2.9
  His337           NE2    O1               2.5
  Lys495           NZ     O2               2.9
  His497           NE2    O1               3.1
  Tyr504           OH     O2               2.5
  Zinc ion                                 
                   Zn     Se               2.7
  Water molecule                           
                   O      O3               2.9
                   O      O3               3.5

Conclusions
===========

There has been considerable interest in applications of selenolate compounds because of their broad therapeutic spectrum and low toxicity. The organoselenium compound ebselen \[2-phenyl-1,2-benzisoselenazol-3(2H)-one\] an anti-inflammatory and general antioxidant, is also a potent inhibitor of extracellular nucleoside diphosphokinase \[[@b26]\]. Furthermore, Achillion Pharmaceuticals (New Haven, CT, USA) has recently developed a selenophene inhibitor of bacterial topoisomerases that shows promise as an antibiotic \[[@b27]\]. However, selenolates have not been exploited as metalloprotease inhibitors despite their antioxidant- and peroxynitrite-scavenging activities. This study has, for the first time, provided molecular details on the binding and coordination of a selenium analogue of the potent ACE inhibitor captopril with ACE and its homologue AnCE. Captopril is one of the smallest ACE inhibitors and with both ACE and AnCE, key interactions of the selenium analogue\'s central carbonyl and proline carboxylate anchor the inhibitor in the cavernous S~1~′S~2~′-binding site of the enzyme. The envelope of space surrounding the P~2~′ proline of SeCap is further illustrated by the accommodation of silylated captopril analogues in the active site of ACE \[[@b28]\]. Selenolates are stronger zinc-binding groups than thiols, yet surprisingly the IC~50~ value of SeCap was greater than that of captopril \[[@b19]\]. This anomaly could be due to the cooperativity of the two-domain somatic ACE and the modest N-domain selectivity of captopril. Structures of SeCap complex with the N-domain and somatic ACE will undoubtedly shed further light on the binding of this new zinc-binding group of compounds with ACE and aid in the design of further selenium-based ACE inhibitors.

Experimental procedures
=======================

tACE--SeCap complex
-------------------

A variant of tACE (tACEΔ36-g13, underglycosylated protein) was purified to homogeneity from Chinese hamster ovary cells \[[@b29]\]. The inhibitor SeCap ([Fig. 1](#fig01){ref-type="fig"}, IC~50~ value of 36.4 ± 1.5 n[m]{.smallcaps}) was synthesized as reported recently \[[@b19]\]. A stock solution (5 m[m]{.smallcaps}) of SeCap was prepared by dissolving the inhibitor in deoxygenated water containing 10 m[m]{.smallcaps} dithiothreitol. The crystals of the tACE complex with SeCap were grown at 16 °C using the hanging drop vapour diffusion method. tACE protein (11.5 mg·mL^−1^ in 50 m[m]{.smallcaps} Hepes, pH 7.5) was preincubated with SeCap (1 m[m]{.smallcaps}) on ice for 3 h before crystallization. Preincubated sample (2 μL) was mixed with the reservoir solution consisting of 13.5% poly(ethylene glycol) 4000, 50 m[m]{.smallcaps} sodium acetate, pH 4.7 and 10 μ[m]{.smallcaps} ZnSO~4~, and suspended above the well. Diffraction quality of cocrystals appeared after ∼ 10 days.

X-ray diffraction data for the tACE--SeCap complex were collected on the PX station IO2 at Diamond Light Source (Didcot, UK). A total of 150 images were collected using a Quantum-4 CCD detector (ADSC Systems, Poway, CA, USA). No cryoprotectant was used to keep the crystal at constant temperature (100 K) under the liquid nitrogen jet during data collection. Raw data images were indexed and scaled with [xds]{.smallcaps} \[[@b30]\] and the CCP4 program [scala]{.smallcaps} \[[@b31]\]. Initial phasing for structure solution was obtained using the molecular replacement routines of the program [phaser]{.smallcaps} \[[@b32]\]. The atomic coordinates of native tACE \[[@b23]\] (PDB code 1O8A) were used as a search model. The resultant model was refined using [refmac5]{.smallcaps} \[[@b33]\] and adjustment of the model was carried out using [coot]{.smallcaps} \[[@b34]\]. Water molecules were added at positions where *F*~o~ − *F*~c~ electron-density peaks exceeded 3σ and potential H-bonds could be made. Based on electron-density interpretation, the inhibitor and sugar moieties were added in the complex structure and further refinement was carried out. The coordinate and parameter files for SeCap were generated using [sketcher]{.smallcaps} \[[@b31]\]. Validation was conducted with the aid of [molprobity]{.smallcaps} \[[@b35]\]. Figures were drawn with [pymol]{.smallcaps} (DeLano Scientific, San Carlos, CA, USA). Hydrogen bonds were verified with the program [hbplus]{.smallcaps} \[[@b25]\]. The detailed refinement statistics for the complex structure are given in [Table 1](#tbl1){ref-type="table"}.

AnCE--SeCap complex
-------------------

AnCE was cloned and expressed in *Pichia pastoris* as described previously \[[@b22]\]. In brief, AnCE was purified to homogeneity from culture media using hydrophobic interaction chromatography and size-exclusion chromatography. The crystals of the AnCE complex with SeCap were grown at 21 °C by the hanging drop vapour diffusion method. AnCE protein (10 mg·mL^−1^ in 50 m[m]{.smallcaps} Hepes, pH 7.5) was preincubated with SeCap (1 m[m]{.smallcaps}) and 10 μ[m]{.smallcaps} zinc acetate, on ice for 3 h before crystallization. Preincubated sample (2 μL) was mixed with the reservoir solution consisting of 1.3 [m]{.smallcaps} sodium citrate, 100 m[m]{.smallcaps} Hepes, pH 7.5 and suspended above the well. Diffraction quality of cocrystals appeared after ∼ 1 week. X-ray diffraction data for the AnCE--SeCap complex were collected on the PX station I24 at Diamond Light Source. A total of 170 images were collected using a PILATUS 6M detector (Dectris, Baden, Switzerland). No cryoprotectant was used. Raw data images were indexed and scaled with [xds]{.smallcaps} \[[@b30]\] and the CCP4 program [scala]{.smallcaps} \[[@b31]\]. Initial phasing for structure solution was obtained using the molecular replacement routines of the program [phaser]{.smallcaps} \[[@b32]\]. The atomic coordinates of native AnCE \[[@b22]\] (PDB code 2X8Y) were used as a search model. The resultant model was refined using [refmac5]{.smallcaps} \[[@b33]\] and adjustment of the model was carried out using [coot]{.smallcaps} \[[@b34]\]. Water molecules were added at positions where *F*~*o*~ *− F*~*c*~ electron-density peaks exceeded 3σ and potential H-bonds could be made. Based on electron-density interpretation, the inhibitor and sugar moieties were added in the complex structure and further refinement was carried out. The coordinate and parameter files for SeCap were generated using [sketcher]{.smallcaps} \[[@b31]\]. Validation was conducted with the aid of [molprobity]{.smallcaps} \[[@b35]\]. Figures were drawn with [pymol]{.smallcaps}. Hydrogen bonds were verified with the program [hbplus]{.smallcaps} \[[@b25]\]. The detailed refinement statistics for the complex structure are given in [Table 1](#tbl1){ref-type="table"}.
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:   angiotensin I-converting enzyme
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:   testis angiotensin I-converting enzyme
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